Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
glycosylphosphatidylinositol (GPI)-anchored cell surface antigen [RGD, Feb 2006].. Additionally we are shipping CD52 Kits (9) and CD52 Proteins (4) and many more products for this protein.
Showing 10 out of 114 products:
Human Monoclonal CD52 Primary Antibody for FACS, IHC (p) - ABIN94170
Rowan, Hale, Tite, Brett: Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. in International immunology 1995
Show all 5 references for ABIN94170
Human Monoclonal CD52 Primary Antibody for FACS - ABIN2662067
Kirchhoff, Krull, Pera, Ivell: A major mRNA of the human epididymal principal cells, HE5, encodes the leucocyte differentiation CDw52 antigen peptide backbone. in Molecular reproduction and development 1993
Show all 4 references for ABIN2662067
Human Monoclonal CD52 Primary Antibody for CyTox, FACS - ABIN317437
Hale, Swirsky, Hayhoe, Waldmann: Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. in Molecular biology & medicine 1985
Show all 4 references for ABIN317437
Human Monoclonal CD52 Primary Antibody for FACS - ABIN2656800
Xia, Hale, Lifely, Ferguson, Campbell, Packman, Waldmann: Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. in The Biochemical journal 1993
Show all 4 references for ABIN2656800
Human Monoclonal CD52 Primary Antibody for FACS, IHC - ABIN2663524
Xia, Tone, Packman, Hale, Waldmann: Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. in European journal of immunology 1991
Show all 3 references for ABIN2663524
Human Monoclonal CD52 Primary Antibody for CyTox, EIA - ABIN320173
Hale, Zhang, Bunjes, Prentice, Spence, Horowitz, Barrett, Waldmann: Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. in Blood 1999
Show all 3 references for ABIN320173
Mouse (Murine) Monoclonal CD52 Primary Antibody for FACS - ABIN2853609
Kubota, Okazaki, Onuma, Kano, Hattori, Minato: Identification and gene cloning of a new phosphatidylinositol-linked antigen expressed on mature lymphocytes. Down-regulation by lymphocyte activation. in Journal of immunology (Baltimore, Md. : 1950) 1991
Soluble CD52 is used by certain CD4 (show CD4 Antibodies)-positive cells to suppress target celss via the inhibitory receptor Siglec-10 (show SIGLEC10 Antibodies).
Genetic background determines the requirement for B7 costimulation in autoimmunity induction. Backcrossed B7.1/B7.2 (show CD86 Antibodies) deficient (-/-)mice on C57BL/6 (B6) or SJL backgrounds had different susceptibility to induced experimental autoimmune encephalomyelitis.
study examined the tissue distribution, molecular composition and immunogenicity of mouse male reproductive tract-CD52
The results indicate CD52 is not required for fertilization in the mouse either in vivo or in vitro.
Study helps to precisely define CD52 expression in the tumor cell population of PTCL and might therefore be valuable when evaluating the response to alemtuzumab therapy in prospective clinical trials.
CD52 is a novel prognostic NSC marker and a potential NSC target in a subset of patients with MDS (show PAFAH1B1 Antibodies) and AML (show RUNX1 Antibodies), which may have clinical implications and may explain clinical effects produced by alemtuzumab in these patients.
A molecular and computational diagnostic approach identifies FOXP3 (show FOXP3 Antibodies), ICOS (show CTLA4 Antibodies), CD52 and CASP1 (show CASP1 Antibodies) as the most informative biomarkers in acute graft-versus-host disease.
CT60 single-nucleotide polymorphism of CTLA4 (show CTLA4 Antibodies) is a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia
Clonal large granular lymphocytes exhibited decreased CD52 expression post-therapy in patients refractory to treatment.
Our bioinformatics findings suggest that CD52 polymorphism may affect the efficiency of GPI (show GNPDA1 Antibodies) anchor formation and thus may indirectly alter the response to anti-CD52 agents like alemtuzumabin renal transplantation.
Review article on CD52 structure and function.
HE5(CD52) mRNA and protein, expressed in epithelial cells of the distal epididymis, were not affected by the obstruction of the vas (show AVP Antibodies) deferens.
The relationship between this differential insertion and differences in glycosylation of rat and human CD52 is discussed.
CD52 is widely expressed on human mast cells (MCs (show SMCP Antibodies)) and Waldenstrom's Macroglobulinemia bone marrow lymphoplasmacytic cells and provide the preclinical rationale for the use of alemtuzumab in the treatment of WM and possibly other MC-related disorders.
In this study, we identified the antigen of 4C8 mAb as CD52. CD52 is a costimulatory molecule (show CD276 Antibodies) for induction of CD4 (show CD4 Antibodies)-positive T cells.
glycosylphosphatidylinositol (GPI)-anchored cell surface antigen
, CD52 antigen
, CAMPATH-1 antigen
, lymphocyte differentiation antigen B7
, CD52 antigen (CAMPATH-1 antigen)
, CDW52 antigen (CAMPATH-1 antigen)
, cambridge pathology 1 antigen
, epididymal secretory protein E5
, human epididymis-specific protein 5